Facing the challenge of social anxiety disorder

European Neuropsychopharmacology

Volumn 9, Issue SUPPL. 3, 1999, Pages

  Westenberg, Herman G M ^a  

^a Academic Hospital Utrecht   (Netherlands)

Author keywords

Benzodiazepines; Monoamine oxidase inhibitors; Paroxetine; Selective serotonin reuptake inhibitors; Social anxiety disorder

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CLONAZEPAM; FLUVOXAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AGORAPHOBIA; ALCOHOLISM; ANXIETY NEUROSIS; CONFERENCE PAPER; DEPRESSION; DRUG ABUSE; DYSTHYMIA; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; OBSESSION; PRIORITY JOURNAL;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; CLINICAL TRIALS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0032803122     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00029-2     Document Type: Conference Paper

References (33)

1. Baldwin, D., Bobes, J., Stein, D.J., Scharwachter, I., and Faure, M. on behalf of the Paroxetine Study Group, 1999. A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder. Br. J. Psychiatry. In press.
2. Ballenger J.C., Davidson J.R.T., Lecrubier Y., et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J. Clin. Psychiatry. 59:(suppl 17):1998;54-60.
3. Davidson J.R.T., Hughes D.L., George L.K., Blazer D.G. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol. Med. 23:1993;709-718.
4. Davidson J.R.T., Potts N., Richichi E., et al. Treatment of social phobia with clonazepam and placebo. J. Clin. Psychopharmacol. 13:1993;423-428.
5. Degonda M., Angst J. The Zurich Study: XX. Social phobia and agoraphobia. Eur. Arch. Psychiatry Clin. Neurosci. 243:1993;95-102.
6. Fahlen T., Nilsson H.L., Borg K., Humble M., Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta. Psychiatr. Scand. 92:1995;351-358.
7. Gelernter C.S., Uhde T.W., Cimbolic P., et al. Cognitive-behavioural and pharmacological treatments of social phobia. A controlled study. Arch. Gen. Psychiatry. 48:1991;938-945.
8. Heimberg R.G., Hope D.A., Dodge C.S., Becker R.E. DSM-III-R subtypes of social phobia: comparison of generalized social phobics and public speaking phobics. J. Nerv. Ment. Dis. 178:1990;172-179.
9. Katzelnick D.J., Kobak K.A., Greist J.H., Jefferson J.W., Mantle J.M., Serlin R.C. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am. J. Psychiatry. 152:1995;1368-1371.
10. Lépine J.-P., Pélissolo A. Social phobia and alcoholism: a complex relationship. J. Affect. Disord. 50:(suppl 1):1998;S23-S28.
11. Liebowitz M.R., Schneier F., Campeas R., et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch. Gen. Psychiatry. 49:1992;290-300.
12. Lott M., Greist J.H., Jefferson J.W., et al. Brofaromine for social phobia: a multicentre, placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 17:1997;255-260.
13. Magee W.J., Eaton W.W., Wittchen H.-U., McGonagle K.A., Kessler R.C. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch. Gen. Psychiatry. 52:1996;159-168.
14. Mannuzza S., Schneier F.R., Chapman T.F., Liebowitz M.R., Klein D.F., Fyer A.J. Generalized social phobia: reliability and validity. Arch. Gen. Psychiatry. 52:1995;230-237.
15. Merikangas K.R., Angst J. Comorbidity and social phobia: evidence from clinical, epidemiologic, and genetic studies. Eur. Arch. Psychiatry Clin. Neurosci. 244:1995;297-303.
16. Noyes R., Moroz G., Davidson J.R.T., et al. Moclobemide in social phobia: a controlled-dose response trial. J. Clin. Psychiatry. 17:1997;247-254.
17. Pohl R., Balon R., Yeragani V.K., Gershon S. Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology. 22:(suppl 1):1989;60-67.
18. Ross J. Social phobia: the consumer's perspective. J. Clin. Psychiatry. 54:(12, suppl):1993;5-9.
19. Schneier F.R., Goetz D., Campeas R., Fallon B., Marshall R., Liebowitz M.R. Placebo-controlled trial of moclobemide in social phobia. Br. J. Psychiatry. 172:1998;70-77.
20. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., Weissman M.M. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch. Gen. Psychiatry. 49:1992;282-288.
21. Schuckit M.A., Hesselbrock V.M. Alcohol dependence and anxiety disorders: what is the relationship? Am. J. Psychiatry. 151:1994;1723-1734.
22. Sheehan D.V., Raj A.B., Harnett-Sheehan K., Soto S., Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta. Psychiatr. Scand. 88:1993;1-11.
23. Stein M.B., Chartier M.J., Hazen A.L., et al. A direct-interview family study of generalized social phobia. Am. J. Psychiatry. 155:1998;90-97.
24. Stein M.B., Chartier M.J., Hazen A.L., Kroft C.D.L., Chale R.A., Cots D., Walker J.R. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16:1996;218-222.
25. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J. Am. Med. Assoc. 280:1998;708-713.
26. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur. Arch. Psychiatry Clin. Neurosci. 247:1997;71-80.
27. van Vliet I.M., den Boer J.A., Westenberg H.G.M. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology. 115:1994;128-134.
28. van Vliet I.M., den Boer J.A., Westenberg H.G.M. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur. Neuropsychopharmacol. 2:1992;21-29.
29. van Vliet I.M., den Boer J.A., Westenberg H.G., Pian K.L. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J. Clin. Psychiatry. 58:1997;164-168.
30. Versiani M., Nardi A.E., Mundim F.D., Alves A.B., Liebowitz M.R., Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br. J. Psychiatry. 161:1992;353-360.
31. Wacker H.R., Millejans R., Klein K.H., Battegay R. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R by using the composite international diagnostic interview (CIDI). Int. J. Meth. Psychiatr. Res. 2:1992;91-100.
32. Weiller E., Bisserbe J.-C., Boyer P., Lepine J.-P., Lecrubier Y. Social phobia in general health care: an unrecognised undertreated disabling disorder. Br. J. Psychiatry. 168:1996;169-174.
33. Wittchen H.-U., Beloch E. The impact of social phobia on quality of life. Int. Clin. Psychopharmacol. 11:(suppl 3):1996;15-23.